2018
Nonalcoholic fatty liver disease impairs expression of the type II inositol 1,4,5‐trisphosphate receptor
Khamphaya T, Chukijrungroat N, Saengsirisuwan V, Mitchell‐Richards K, Robert ME, Mennone A, Ananthanarayanan M, Nathanson MH, Weerachayaphorn J. Nonalcoholic fatty liver disease impairs expression of the type II inositol 1,4,5‐trisphosphate receptor. Hepatology 2018, 67: 560-574. PMID: 29023819, PMCID: PMC5893412, DOI: 10.1002/hep.29588.Peer-Reviewed Original ResearchConceptsNonalcoholic fatty liver diseaseImpaired liver regenerationNonalcoholic steatohepatitisLiver regenerationHuh7 cellsLiver diseaseEffect of NAFLDPrevalent liver diseaseFatty liver diseaseC-JunHigh-fructose dietLiver biopsy specimensCell proliferationCalcium signalingHepG2 cellsLiver of ratsCell nuclear antigenCalcium release channelSimple steatosisLiver biopsyFatty liverTrisphosphate receptorBiopsy specimensRat modelType II inositol
2016
Effects of andrographolide on intrahepatic cholestasis induced by alpha-naphthylisothiocyanate in rats
Khamphaya T, Chansela P, Piyachaturawat P, Suksamrarn A, Nathanson MH, Weerachayaphorn J. Effects of andrographolide on intrahepatic cholestasis induced by alpha-naphthylisothiocyanate in rats. European Journal Of Pharmacology 2016, 789: 254-264. PMID: 27475677, PMCID: PMC10804355, DOI: 10.1016/j.ejphar.2016.07.032.Peer-Reviewed Original ResearchConceptsCholestatic liver diseaseLiver diseaseIntrahepatic cholestasisLiver injuryProtective effectHepatic stellate cell activationAcute intrahepatic cholestasisAlpha-smooth muscle actinCholestatic liver injuryBile duct proliferationSerum alanine aminotransferaseNF-κB expressionSingle intraperitoneal injectionEffects of andrographolidePromising therapeutic optionEffective therapeutic approachPotent protective propertiesNuclear factor kappaStellate cell activationANIT injectionDuct proliferationTherapeutic optionsHepatoprotective effectPeriductular fibrosisAlternative therapies